All Disease Research articles
-
NewsNew malaria mutations linked to resistance against multiple front-line drugs
Whole-genome sequencing of parasites from Ugandan patients has uncovered a cluster of genetic variants linked to reduced susceptibility to multiple front-line malaria treatments, with researchers warning the mutations are spreading rapidly.
-
NewsGLP-1 drug semaglutide extends lifespan and slows ageing in older mice
A new NIH-funded study suggests the GLP-1 receptor agonist semaglutide may slow biological ageing and extend lifespan in older mice, raising the prospect that GLP-1 drugs could one day be developed as broad longevity-enhancing interventions.
-
ArticleWhy depression needs a different drug discovery strategy
What if depression is not one disease, but many biologically distinct conditions? A major research programme is investigating what this could mean for biomarkers, drug targets and treatment.
-
NewsPatient-derived tumour organoid biobank maps cancer gene dependencies
A biobank of 256 patient-derived tumour organoids, combined with genome-wide CRISPR–Cas9 screening, has produced a detailed map of cancer gene dependencies across five tumour types, revealing both shared vulnerabilities and mutation-specific targets with implications for precision oncology.
-
NewsBRAF identified as novel target for neuropathic pain treatment
Researchers at MD Anderson Cancer Center have discovered that BRAF, a protein well known for its role in cancer, may also drive chronic pain following nerve injury – raising the prospect of repurposing approved cancer drugs as treatments for neuropathic pain.
-
NewsStem cell-grown kidney organoids could help uncover new treatments for AKI
Researchers at Monash University have grown miniature human kidneys from stem cells that could give drug discovery teams a more human-relevant model for investigating acute kidney injury and identifying therapies that promote tissue recovery.
-
ArticleTargeting childhood myopia progression with 7-methylxanthine
Childhood myopia researcher Dr Klaus Trier explores how 7-methylxanthine targets scleral remodelling and axial elongation, and its potential to slow disease progression and reduce the risk of high myopia.
-
NewsHuman heart organoids with functioning valves model cardiac valve disorders
Researchers have engineered human heart organoids complete with functioning valves, creating a physiologically relevant platform to study valve disorders including mitral valve prolapse and valve calcification, and potentially accelerating the search for new treatments.
-
NewsMeis2 gene identified as potential therapeutic target for neurodevelopmental disorders
A gene therapy targeting parvalbumin inhibitory neurons has restored experience-dependent plasticity and reduced seizure frequency in a mouse model of neurodevelopmental disorders, offering a potential new avenue for treating autism spectrum disorder and epilepsy.
-
ArticleFibroblast barrier linked to immunotherapy resistance in colorectal cancer
Why do some colorectal cancers resist immunotherapy? Analysis of patient tumour samples has identified a population of fibroblasts that could help explain treatment resistance.
-
ArticleGene therapy’s biggest challenge is the cell’s own defence mechanisms
What if one of gene therapy’s biggest obstacles isn’t delivery, but the body’s own cells? Discover why DNA silencing is emerging as a major challenge for long-lasting genetic medicines.
-
NewsGlymphatic gene therapy platform targets brain’s glial cells precisely
A new gene therapy platform exploiting the brain’s glymphatic transport system and engineered AAV5 vectors could offer a targeted treatment route for multiple sclerosis, Huntington’s disease and rare white matter disorders.
-
NewsBMP3 protein identified as therapeutic target for pulmonary arterial hypertension
Scientists at the Fralin Biomedical Research Institute have identified bone morphogenetic protein 3 as a protective factor in lung blood vessels, with preclinical data showing that restoring its levels can reverse hallmark features of pulmonary arterial hypertension.
-
NewsBlood test for protein misfolding identifies Alzheimer’s risk years before symptoms
A blood-based biomarker measuring amyloid beta protein misfolding has demonstrated superior predictive accuracy for pre-symptomatic Alzheimer’s disease compared with p-tau 217, achieving an AUC of 0.87 when combined with genetic and demographic data.
-
NewsLandmark fibromyalgia study highlights neurological targets for new therapies
A landmark genome-wide study of more than 2.5 million adults has identified 26 genomic regions linked to fibromyalgia, confirming a neurological basis for the condition and opening new avenues for targeted drug discovery.
-
WebinarOligonucleotide therapeutics safety considerations across drug development
As oligonucleotide therapeutics continue to advance, their safety assessment presents challenges that differ from traditional drug modalities. Discover how nonclinical safety studies, evolving regulatory expectations and real-world case examples can help you navigate these challenges with greater confidence.
-
News3D genome reorganisation identified as Alzheimer’s disease molecular hallmark
An international study combining single-cell genomics, spatial transcriptomics and artificial intelligence has identified large-scale changes in three-dimensional genome organisation in Alzheimer’s-affected brain cells, establishing chromatin architecture as a previously overlooked component of the disease’s molecular pathology and a potential framework for future therapeutic targeting.
-
ArticleMaking historical toxicology data work harder in safety assessment
Historical toxicology data is often underused. Find out how Virtual Control Groups and AI could help researchers strengthen safety assessment while making better use of existing data.
-
NewsNew drug target identified to protect hearts in DMD patients
Researchers at the University of South Florida have identified NOX4 as a potential therapeutic target for DMD-related cardiomyopathy, with experimental drug Setanaxib demonstrating cardioprotective effects in preclinical models.
-
NewsNew drug SB-0110 targets levodopa’s two biggest clinical limitations for Parkinson’s
A computational biology-derived compound has shown promise in preclinical models by simultaneously improving levodopa response and reducing dyskinesia — two of the most significant challenges in long-term Parkinson’s disease management.